The evaluation and treatment of Paget's disease of bone

被引:9
|
作者
Singer, Frederick R. [1 ,2 ]
机构
[1] John Wayne Canc Inst, Providence St Johns Hlth Ctr, Endocrine Bone Dis Program, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA
[2] UCLA, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA
来源
关键词
Bone pain; Deformity; Familial; Drug therapy; Surgery; ACUTE-PHASE RESPONSE; GIANT-CELL TUMOR; OSTEOCLASTS; CALCITONIN; DENOSUMAB; GENE; MUTATIONS; VIRUS; ACID; HISTOMORPHOMETRY;
D O I
10.1016/j.berh.2020.101506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paget's disease of bone is a localized skeletal disorder, which is more common in England and in countries to which the English migrated. In recent decades, the prevalence in most countries has decreased. A family history of the disorder is present in approximately 15% of patients. Patients may be asymptomatic and may be diagnosed accidently as a consequence of an elevated serum alkaline phosphatase level or a finding on an x-ray or nuclear bone scan. The diagnosis is made by x-ray but nuclear bone scans define the extent of the disease. Salmon calcitonin and bisphosphonate drugs have proven effective, but by far, the most effective therapy is a single 5 mg intravenous infusion of zoledronic acid. This can normalize alkaline phosphatase levels for up to 6.5 years. A variety of gene mutations may predispose individuals to develop the disease but environmental factors such as measles virus likely play an important role. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Treatment of Paget's disease of bone
    Lojo Oliveira, Leticia
    Torrijos Eslava, Antonio
    [J]. REUMATOLOGIA CLINICA, 2012, 8 (04): : 220 - 224
  • [2] Treatment of Paget's Disease of Bone
    Urteaga, Elizabeth M.
    [J]. US PHARMACIST, 2012, 37 (10) : 29 - 34
  • [3] Treatment of Paget's disease of bone
    Arias M, Garcia
    Eslava A, Torrijos
    [J]. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2011, 3 (01) : 35 - 40
  • [4] An economic evaluation of tiludronic acid treatment in Paget's disease of bone
    Lafuma, A
    Fagnani, F
    Meunier, PJ
    [J]. PHARMACOECONOMICS, 1997, 12 (04) : 460 - 474
  • [5] An Economic Evaluation of Tiludronic Acid Treatment in Paget’s Disease of Bone
    Antoine Lafuma
    Francis Fagnani
    Pierre J. Meunier
    [J]. PharmacoEconomics, 1997, 12 : 460 - 474
  • [6] Alendronate in the treatment of Paget's disease of bone
    Khan, SA
    Vasikaran, S
    McCloskey, EV
    Beneton, MNC
    Rogers, S
    Coulton, L
    Orgee, J
    Coombes, G
    Kanis, JA
    [J]. BONE, 1997, 20 (03) : 263 - 271
  • [7] Diagnosis and treatment of Paget's disease of bone
    Schneider, D
    Hofmann, MT
    Peterson, JA
    [J]. AMERICAN FAMILY PHYSICIAN, 2002, 65 (10) : 2069 - 2072
  • [8] Treatment of patients with Paget's disease of bone
    Roux, C
    Dougados, M
    [J]. DRUGS, 1999, 58 (05) : 823 - 830
  • [9] TREATMENT OF PAGET'S BONE DISEASE WITH A BISPHOSPHONATE
    Fromm, G. A.
    Plantalech, Luisa
    Casco, Cristina
    Gonzalez, Diana
    Mautalen, C. A.
    [J]. ACTUALIZACIONES EN OSTEOLOGIA, 2020, 16 : 36 - 42
  • [10] Paget's disease of bone: Complications and treatment
    Alexandre, C
    [J]. REVUE DU RHUMATISME, 1997, 64 (06): : S99 - S102